ASP Isotopes Inc.

ASP Isotopes Inc. is a development-stage chemicals company focused on the production and distribution of specialized isotopes for industrial and medical applications. The company operates proprietary separation technologies, including its Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) platform, which enable the isolation of isotopes from various source materials. Its product portfolio spans multiple end markets, including nuclear fuels, nuclear medicine imaging, pharmaceuticals, agrochemicals, and semiconductors.

The company operates through two primary segments. Its Nuclear Fuels segment conducts research and development on technologies for producing high-assay low-enriched uranium (HALEU) and Lithium-6, targeting the advanced nuclear fuels market. The Specialist Isotopes and Related Services segment focuses on separating high-value, low-volume isotopes such as Molybdenum-100, Carbon-14, and Silicon-28, alongside the operation of PET imaging laboratories. Current commercialized isotope products include Molybdenum-100 and Molybdenum-98 for nuclear medical applications, with development programs underway for Zinc, Nickel, Xenon, Lithium, Uranium, Chlorine, and Germanium isotopes across various industries.

Incorporated in 2021 and headquartered in Dallas, Texas, the company maintains a workforce of 136 full-time employees. ASP Isotopes remains in early commercialization stages, with operations primarily based in the United States.